首页 | 本学科首页   官方微博 | 高级检索  
     检索      

全球生物制药行业专利态势分析
引用本文:王春丽,黄瑶庆,李子艳,毛艳艳.全球生物制药行业专利态势分析[J].科技导报(北京),2021,39(2):73-82.
作者姓名:王春丽  黄瑶庆  李子艳  毛艳艳
作者单位:中国科学院上海药物研究所信息中心, 上海 201203
摘    要: 从专利统计分析角度,分析了生物制药领域发展的现状及趋势、技术发展的重点和热点。研究发现,全球生物制药技术发展已趋于成熟,抗肿瘤药物领域依然是研发热点。美国是生物制药领域创新实力的代表,中国专利申请近年来不断攀升,但质量有待提高。国内外制药公司依然是药物研发的主力军,科研机构也不断给生物制药行业带来新助力。CRIS-PR-Cas系统技术、PD-1/PD-L1免疫疗法以及CAR-T细胞疗法是目前生物制药领域的热门技术。

关 键 词:生物制药  专利分析  发展态势  免疫疗法  CRISPR-Cas  
收稿时间:2019-09-20

Analysis of patents in global biopharmaceutical industry
WANG Chunli,HUANG Yaoqing,LI Ziyan,MAO Yanyan.Analysis of patents in global biopharmaceutical industry[J].Science & Technology Review,2021,39(2):73-82.
Authors:WANG Chunli  HUANG Yaoqing  LI Ziyan  MAO Yanyan
Institution:Information Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
Abstract:In recent years, the global biopharmaceutical industry is developing rapidly. With a statistical analysis of the patents, this paper analyzes the current situation and the trend of the biopharma development, the focuses and the hotspots of the technological development, to provide a reference for the industrial decision-making and policy-making. The analysis shows that the global biopharma development is quite mature, and the development of anti-cancer drugs is still a hot spot in recent years. The United States is the innovation representative and the patent applications in China increase in recent years, though the quality remains to be improved. Companies are still the main force in the drug research and development, and the scientific research institutions are constantly providing new impetus to the biopharma industry. The CRISPR-Cas system, the PD-1/PD-L1 immunotherapy and the CAR T -cell therapy are leading technologies in this field.
Keywords:biopharma  patent analysis  development trend  immunotherapy  CRISPR-Cas  
本文献已被 万方数据 等数据库收录!
点击此处可从《科技导报(北京)》浏览原始摘要信息
点击此处可从《科技导报(北京)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号